Table 3.
Adjusted mean changes in total antidiabetes medication prescriptions and total insulin prescriptions from pre- to post-ACA between insurance groups
| Measure | Continuously uninsured | Discontinuously insured | Continuously insured | Newly insured |
|---|---|---|---|---|
| Total antidiabetes medication prescriptions | ||||
| Pre-ACA, mean | 25.3 | 25.7 | 24.5 | 22.2 |
| Post-ACA, mean | 26.8 | 34.8 | 30.0 | 33.4 |
| Change pre- to post-ACA | +1.5 | +9.1 | +5.5 | +11.2 |
| DID | −9.7 | −2.0 | −5.7 | Ref |
| 95% CI | −11.4 to −8.0 | −3.4 to −0.5 | −7.2 to −4.2 | Ref |
| P value | <0.001 | 0.009 | <0.001 | Ref |
| Insulin prescriptions | ||||
| Pre-ACA, mean | 6.5 | 7.3 | 6.5 | 6.4 |
| Post-ACA, mean | 7.4 | 11.9 | 9.0 | 11.0 |
| Change pre- to post-ACA | +0.9 | +4.6 | +2.5 | +4.6 |
| DID | −3.7 | −0.0 | −2.1 | Ref |
| 95% CI | −4.8 to −2.5 | −1.0 to 1.0 | −3.1 to −1.1 | Ref |
| P value | <0.001 | 0.944 | <0.001 | Ref |
Prescription-adjusted means at each period (pre- and post-ACA) and for each insurance group were estimated using a linear mixed-effects model. Random effects for patients and CHCs accounted for temporal observations of biomarkers within patients as well as for patients nested with CHCs. Boldface type denotes statistical significance (i.e., P < 0.05). Ref, reference.